Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vertex (VRTX) PT Raised to $285 at SunTrust
January 31, 2020 6:40 AM ESTSunTrust analyst Robyn Karnauskas raised the price target on Vertex (NASDAQ: VRTX) to $285.00 (from $235.00) while maintaining a Buy rating following results.
The analyst commented, "Recent approval of VRTX's drug TRIKAFTA and strong early launch metrics de-risk CF revenues for VRTX, in our... More
Vertex Pharma (VRTX) Tops Q4 EPS by 50c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus
January 30, 2020 4:04 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $1.70, $0.50 better than the analyst estimate of $1.20. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.01 billion.
"In 2019, our differentiated strategy of investing in serial scientific innovation to create transformative medicines... More
